BioCentury | Feb 13, 2012
Company News

AGI Therapeutics, Aravis Therapeutics deal

...€10.7 million ($14 million). The offer remains open until Feb. 17 (see BioCentury, Jan. 16). AGI Therapeutics plc...
BioCentury | Jan 16, 2012
Company News

AGI Therapeutics, Aravis Therapeutics deal

...Aravis began its tender offer to acquire AGI Therapeutics for €10.7 million ($13.6 million) in cash. AGI's...
...AGI-022 to Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) for $300,000 (see BioCentury, Aug. 1, 2011). AGI Therapeutics plc...
BioCentury | Aug 1, 2011
Company News

AGI Therapeutics, Warner Chilcott deal

...deal includes rights to an undisclosed compound for treating gastrointestinal conditions. Details were not disclosed. AGI Therapeutics plc...
BioCentury | Oct 28, 2010
Targets & Mechanisms

STEP against AD

Yale University researchers have made a case for blocking STEP, a brain-specific phosphatase involved in synaptic signaling and a key player in the early stages of Alzheimer's disease development. 1 Knocking down the enzyme forestalled...
BioCentury | Nov 2, 2009
Company News

Questcor management update

...David Young, a director, as CSO, formerly executive director and president of U.S. operations of AGI Therapeutics plc WIR...
BioCentury | Aug 24, 2009
Company News

AGI Therapeutics, TPG Capital deal

...Therapeutics regained full rights to AGI-010 after TPG Capital 's Axcan Pharma Inc. unit and AGI Therapeutics...
...for NAB. Axcan said the compound was no longer in line with its core strategy. AGI Therapeutics...
...Act, said it plans to seek another partner for AGI-010. TPG acquired Axcan in 2008. AGI Therapeutics plc...
BioCentury | Jul 6, 2009
Finance

2Q Approvals & Setbacks

...increased risk of fracture 2Q setbacks Selected second quarter clinical and regulatory setbacks. Company Setback AGI Therapeutics plc...
BioCentury | May 18, 2009
Finance

Ebb & Flow

...was up $0.72 (14%) to $6.03, and Enzon tacked on $0.17 to $6.54. Clinical milestones AGI Therapeutics plc...
BioCentury | May 18, 2009
Clinical News

Arverapamil: Development discontinued

...no significant differences between Rezular and placebo in pain relief or change in pain severity. AGI Therapeutics plc...
BioCentury | May 16, 2009
Top Story

AGI discontinues Rezular

AGI Therapeutics plc (ISE:A9I; LSE:AGI) closed down 23.5p (59%) to 16p on LSE and down EUR 0.32 (68%) to EUR 0.15 on ISE on Friday after discontinuing development of Rezular arverapamil for diarrhea-predominant irritable bowel...
Items per page:
1 - 10 of 80
BioCentury | Feb 13, 2012
Company News

AGI Therapeutics, Aravis Therapeutics deal

...€10.7 million ($14 million). The offer remains open until Feb. 17 (see BioCentury, Jan. 16). AGI Therapeutics plc...
BioCentury | Jan 16, 2012
Company News

AGI Therapeutics, Aravis Therapeutics deal

...Aravis began its tender offer to acquire AGI Therapeutics for €10.7 million ($13.6 million) in cash. AGI's...
...AGI-022 to Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland) for $300,000 (see BioCentury, Aug. 1, 2011). AGI Therapeutics plc...
BioCentury | Aug 1, 2011
Company News

AGI Therapeutics, Warner Chilcott deal

...deal includes rights to an undisclosed compound for treating gastrointestinal conditions. Details were not disclosed. AGI Therapeutics plc...
BioCentury | Oct 28, 2010
Targets & Mechanisms

STEP against AD

Yale University researchers have made a case for blocking STEP, a brain-specific phosphatase involved in synaptic signaling and a key player in the early stages of Alzheimer's disease development. 1 Knocking down the enzyme forestalled...
BioCentury | Nov 2, 2009
Company News

Questcor management update

...David Young, a director, as CSO, formerly executive director and president of U.S. operations of AGI Therapeutics plc WIR...
BioCentury | Aug 24, 2009
Company News

AGI Therapeutics, TPG Capital deal

...Therapeutics regained full rights to AGI-010 after TPG Capital 's Axcan Pharma Inc. unit and AGI Therapeutics...
...for NAB. Axcan said the compound was no longer in line with its core strategy. AGI Therapeutics...
...Act, said it plans to seek another partner for AGI-010. TPG acquired Axcan in 2008. AGI Therapeutics plc...
BioCentury | Jul 6, 2009
Finance

2Q Approvals & Setbacks

...increased risk of fracture 2Q setbacks Selected second quarter clinical and regulatory setbacks. Company Setback AGI Therapeutics plc...
BioCentury | May 18, 2009
Finance

Ebb & Flow

...was up $0.72 (14%) to $6.03, and Enzon tacked on $0.17 to $6.54. Clinical milestones AGI Therapeutics plc...
BioCentury | May 18, 2009
Clinical News

Arverapamil: Development discontinued

...no significant differences between Rezular and placebo in pain relief or change in pain severity. AGI Therapeutics plc...
BioCentury | May 16, 2009
Top Story

AGI discontinues Rezular

AGI Therapeutics plc (ISE:A9I; LSE:AGI) closed down 23.5p (59%) to 16p on LSE and down EUR 0.32 (68%) to EUR 0.15 on ISE on Friday after discontinuing development of Rezular arverapamil for diarrhea-predominant irritable bowel...
Items per page:
1 - 10 of 80